Biolinq Shine, Insulin Icodec, and Eli Lilly's Pipeline

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, explore 3 significant developments shaping diabetes care: a novel glucose-sensing technology, the return of once-weekly insulin icodec to the US Food and Drug Administration (FDA), and changes to Eli Lilly’s metabolic research pipeline.

00:00:01 Introduction

00:00:18 The Biolinq Shine

00:05:59 The Practicality of Monitoring Glucose

00:06:55 Wishlist for the Biolinq's Future

00:08:38 Insulin Icodec Resubmission

00:10:21 Benefits of Once-Weekly Insulin

00:14:00 International Success Stories

00:15:28 Eli Lilly Cancels Bimagrumab for T2D

00:18:36 Bimagrumab Still in Testing for Obesity

00:22:49 Outro